Sharescart Research Club logo
Products
Research
Tools
About
Join Channel

Pfizer

₹4623 -74.5 | 1.6%

Last updated: 15:49

Consolidated Standalone

Last updated: 15:49

Pfizer Overview

Pfizer Ltd is an India-based pharmaceutical agency. The Company has a portfolio of approximately 150 products across over 15 therapeutic areas. The Company is engaged in production, advertising, buying and selling and exporting pharmaceutical products. The Company gives various merchandise for anti-diabetic, erectile disorder, gastrointestinal (GI), multivitamins, anti-infectives, cardiovascular, dermatology, neurology, ache/fever/infection and autoimmune problems, amongst others. Its merchandise consist of Viagra, Daxid, Tricorex, Mucaine, Di...Read More

Want to Start Investing in Top Unlisted Stocks?

Our experts help you choose the right stocks based on performance, risk, and growth potential.

Pfizer Key Financials

Market Cap ₹21149 Cr.

Stock P/E 27.6

P/B 5.3

Current Price ₹4623

Book Value ₹ 872.2

Face Value 10

52W High ₹5987.7

Dividend Yield 3.57%

52W Low ₹ 3742.9

Edit Ratio

Pfizer Share Price

₹ | |

Volume
Price

Pfizer Quarterly Price

Quarterly Monthly
Show Value Show %

Pfizer Peer Comparison

Pfizer Quarterly Results

#(Fig in Cr.) Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025
Net Sales 575 540 547 563 589 538 592 603 642 645
Other Income 36 36 75 42 43 43 45 67 42 38
Total Income 611 576 622 605 632 581 636 670 684 683
Total Expenditure 393 387 357 385 399 392 364 393 412 417
Operating Profit 219 188 265 219 232 189 272 277 272 266
Interest 3 3 7 2 2 2 3 3 2 2
Depreciation 15 18 14 15 15 15 16 14 14 14
Exceptional Income / Expenses 0 8 0 0 0 0 173 0 0 -58
Profit Before Tax 201 176 244 203 215 172 426 260 255 192
Provision for Tax 52 46 65 52 57 45 95 68 66 50
Profit After Tax 149 130 179 151 158 128 331 192 189 142
Adjustments 0 0 0 0 0 0 0 0 0 0
Profit After Adjustments 149 130 179 151 158 128 331 192 189 142
Adjusted Earnings Per Share 32.6 28.4 39.1 32.9 34.6 27.9 72.3 41.9 41.3 31

Pfizer Profit & Loss

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
Net Sales 1853 2012 1966 1969 2082 2152 2239 2611 2425 2193 2281 2482
Other Income 72 87 101 114 167 184 81 63 101 181 172 192
Total Income 1925 2099 2067 2083 2249 2336 2320 2674 2526 2374 2454 2673
Total Expenditure 1474 1579 1616 1468 1516 1579 1526 1775 1616 1558 1541 1586
Operating Profit 451 520 451 615 733 757 794 899 910 816 913 1087
Interest 2 1 2 1 2 11 15 11 13 15 9 10
Depreciation 131 58 63 66 71 103 109 115 106 62 61 58
Exceptional Income / Expenses -80 10 130 0 0 0 0 0 33 8 173 115
Profit Before Tax 238 470 517 548 660 642 669 773 824 746 1016 1133
Provision for Tax 138 165 180 188 231 133 171 160 200 195 248 279
Profit After Tax 100 305 337 360 429 509 498 613 624 551 768 854
Adjustments -31 0 0 0 0 0 0 0 0 0 0 0
Profit After Adjustments 70 305 337 360 429 509 498 613 624 551 768 854
Adjusted Earnings Per Share 21.9 66.7 73.6 78.7 93.8 111.3 108.8 133.9 136.4 120.5 167.8 186.5

Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 4% -4% 1% 2%
Operating Profit CAGR 12% 1% 4% 7%
PAT CAGR 39% 8% 9% 23%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR 14% 8% 0% 10%
ROE Average 20% 19% 19% 16%
ROCE Average 26% 25% 26% 23%

Pfizer Balance Sheet

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Shareholder's Funds 1973 2163 2419 2683 3011 3395 2393 2864 3207 3596 4217
Minority's Interest 0 0 0 0 0 0 0 0 0 0 0
Borrowings 3 3 0 0 0 0 0 0 0 0 0
Other Non-Current Liabilities -37 64 62 52 37 136 85 136 38 33 55
Total Current Liabilities 609 658 780 954 892 873 774 853 657 547 570
Total Liabilities 2547 2888 3261 3690 3940 4405 3252 3854 3903 4175 4842
Fixed Assets 944 925 867 917 854 942 865 841 749 713 724
Other Non-Current Assets 350 331 343 357 371 415 479 616 629 693 605
Total Current Assets 1252 1614 2033 2403 2702 3013 1873 2361 2493 2738 3513
Total Assets 2547 2888 3261 3690 3940 4405 3252 3854 3903 4175 4842

Pfizer Cash Flow

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Opening Cash & Cash Equivalents 308 488 71 68 51 74 1764 151 63 37 112
Cash Flow from Operating Activities 113 345 329 332 98 323 427 667 356 257 660
Cash Flow from Investing Activities -89 -701 -250 -238 35 1530 -469 -575 -36 54 -71
Cash Flow from Financing Activities -1 -62 -83 -110 -110 -164 -1571 -181 -346 -235 -205
Net Cash Inflow / Outflow 23 -417 -3 -17 23 1690 -1613 -88 -26 75 383
Closing Cash & Cash Equivalent 488 71 68 51 74 1764 151 63 37 112 495

Pfizer Ratios

# Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Earnings Per Share (Rs) 21.93 66.67 73.61 78.7 93.78 111.29 108.77 133.89 136.38 120.51 167.78
CEPS(Rs) 50.59 79.33 87.37 93.18 109.39 133.85 132.68 159.03 159.44 134.12 181.07
DPS(Rs) 12.5 15 20 20 22.5 330 35 30 70 35 165
Book NAV/Share(Rs) 431.28 472.92 528.72 586.49 658.22 742.18 523.07 626.1 701.05 785.91 921.84
Core EBITDA Margin(%) 19.69 20.67 17.15 25.28 27.17 26.62 31.82 30.79 31.6 27.43 31.01
EBIT Margin(%) 12.43 22.53 25.41 27.71 31.79 30.37 30.56 28.86 32.71 32.88 42.91
Pre Tax Margin(%) 12.36 22.47 25.31 27.67 31.7 29.86 29.87 28.46 32.18 32.21 42.56
PAT Margin (%) 5.21 14.57 16.49 18.18 20.61 23.66 22.23 22.56 24.37 23.81 32.15
Cash Profit Margin (%) 12.01 17.33 19.58 21.53 24.04 28.46 27.12 26.79 28.49 26.49 34.7
ROA(%) 5.75 11.22 10.95 10.36 11.25 12.2 13 17.24 16.09 13.65 17.03
ROE(%) 7.63 14.75 14.7 14.11 15.07 15.89 17.19 23.3 20.55 16.21 19.65
ROCE(%) 18.19 22.78 22.62 21.49 23.22 20.38 23.62 29.78 27.56 22.37 26.21
Receivable days 31.59 26.35 22.58 24.43 28.62 29.15 22.89 16.89 20.98 26.74 29.1
Inventory Days 51.1 65.25 61.01 57.05 59.95 69.32 70.57 59.41 61.77 67.09 69.53
Payable days 138.79 175.52 186.15 238.01 250.57 212.28 176.59 114.15 109.36 95.85 76.77
PER(x) 101.69 26.8 25.71 27.77 35.41 36.17 41.57 32.5 25.4 34.8 23.86
Price/Book(x) 5.17 3.78 3.58 3.73 5.04 5.42 8.64 6.95 4.94 5.34 4.34
Dividend Yield(%) 0.56 0.84 1.06 0.92 0.68 8.2 0.77 0.69 2.02 0.83 4.12
EV/Net Sales(x) 5.18 3.55 3.63 4.18 6.38 7.53 8.74 7 5.77 7.82 6.8
EV/Core EBITDA(x) 21.28 13.76 15.82 13.38 18.12 21.4 24.67 20.33 15.37 21.01 17.01
Net Sales Growth(%) 66.69 8.58 -2.29 0.11 5.74 3.37 4.04 16.64 -7.13 -9.55 4.02
EBIT Growth(%) -29.69 96.98 9.96 5.76 20.59 -1.23 4.68 14.54 6.88 -9.07 34.55
PAT Growth(%) -54.57 203.95 10.43 6.92 19.16 18.66 -2.26 23.1 1.86 -11.64 39.23
EPS Growth(%) -70.36 203.95 10.42 6.92 19.16 18.66 -2.26 23.1 1.86 -11.64 39.23
Debt/Equity(x) 0 0 0 0 0 0 0 0 0 0 0
Current Ratio(x) 2.06 2.45 2.61 2.52 3.03 3.45 2.42 2.77 3.79 5.01 6.17
Quick Ratio(x) 1.42 1.9 2.19 2.21 2.6 2.96 1.87 2.24 3.16 4.22 5.33
Interest Cover(x) 158.68 337.93 264.69 712.57 384.67 59.36 44.45 73.23 62.13 49.35 120.54
Total Debt/Mcap(x) 0 0 0 0 0 0 0 0 0 0 0

Pfizer Shareholding Pattern

# Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025
Promoter 63.92 63.92 63.92 63.92 63.92 63.92 63.92 63.92 63.92 63.92
FII 2.82 3.03 3.32 3.22 3.54 2.75 2.18 2.39 2.6 2.71
DII 15.01 15.15 15.33 15.84 16.03 16.79 17.1 17.23 17.1 17.05
Public 18.25 17.9 17.42 17.02 16.5 16.54 16.8 16.45 16.37 16.32
Others 0 0 0 0 0 0 0 0 0 0
Total 100 100 100 100 100 100 100 100 100 100

Pfizer News

Pfizer Pros & Cons

Pros

  • Debtor days have improved from 95.85 to 76.77days.
  • Company is almost debt free.

Cons

  • Stock is trading at 5.3 times its book value.
  • The company has delivered a poor profit growth of 8% over past five years.

* The pros and cons are machine generated.

You May Also Know About

Unlisted Shares Pre-IPO Shares ESOP Shares Delisted Shares
whatsapp

Please Login!

Click to Login
OR
Get free Account

Error!